Mona El-Gamil

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

S. Rosenberg, R. Morgan, P. Robbins, 2007, Cancer research.

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Sadik H. Kassim, M. Raffeld, S. Rosenberg, 2014, Clinical Cancer Research.

Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines

Paul Polakis, Paul Robbins, P. Robbins, 1997, Science.

Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions

Bent K. Jakobsen, Richard A. Morgan, Steven A. Rosenberg, 2008, The Journal of Immunology.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

M. Raffeld, S. Rosenberg, R. Morgan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.